This is Hansa
We are a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
A fast-growing biopharma company
Hansa Biopharma was founded in 2007, with the corporate headquarters in Lund, Sweden. We also have operations in other European countries and in the US. We have been listed on the Nasdaq First North Growth Market Stockholm from 2007 to 2015 and on the Nasdaq Stockholm since 2015.
Our technology platform
We have developed our proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease causing antibodies. Our broad therapeutic pipeline has potential applications across transplantation, autoimmune diseases, gene therapy and oncology indications addressing significant unmet medical needs.
A fully integrated commercial-stage biopharma
We focus on developing innovative lifesaving and life altering therapies that can address the significant unmet medical needs of patients with rare immunological conditions.
Hansa Biopharma is an innovative biopharmaceutical company, headquarter in Lund, Sweden and with operations in other European countries and in the U.S. Listed on the Nasdaq Stockholm.
At Hansa, we push boundaries to progress and succeed, and in everything we want to go from good to great. There are golden opportunities for highly talented, dedicated, and passionate people to join us on our journey.
One platform, many therapeutic opportunities
Our broad therapeutic pipeline has potential applications across transplantation, autoimmune diseases, gene therapy and oncology indications.
Our proprietary technology platform with imliﬁdase and next generation enzymes has signiﬁcant patent protection beyond 2035.
We have collaborations with leading research clinics and a growing number of partnerships with industry, healthcare and academia.